UBS Group AG Acquires 125,521 Shares of STERIS plc $STE

Key Points

• UBS Group AG boosted its stake in STERIS by 32.4%, buying 125,521 shares to own 512,573 shares worth about $129.95 million (roughly 0.52% of the company).
• STERIS posted Q EPS of $2.53 (in line) with revenue up 9.2% YoY and set FY2026 guidance of $10.15–$10.30 EPS; analysts maintain a consensus "Moderate Buy" with an average target of $275.20 versus a current price near $214.78.

UBS Group AG grew its holdings in STERIS plc (NYSE:STE - Free Report) by 32.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 512,573 shares of the medical equipment provider's stock after acquiring an additional 125,521 shares during the period. UBS Group AG owned 0.52% of STERIS worth $129,948,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Steigerwald Gordon & Koch Inc. bought a new stake in shares of STERIS during the 3rd quarter valued at $25,000. Board of the Pension Protection Fund bought a new stake in shares of STERIS during the 4th quarter valued at $25,000. Harbor Investment Advisory LLC raised its position in shares of STERIS by 115.4% during the 4th quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 60 shares during the period. Cloud Capital Management LLC bought a new stake in shares of STERIS during the 3rd quarter valued at $29,000. Finally, Geneos Wealth Management Inc. raised its position in shares of STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 104 shares during the period. 94.69% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

STE has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of STERIS from a "strong-buy" rating to a "buy" rating in a research report on Sunday, April 26th. Weiss Ratings lowered shares of STERIS from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, April 16th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, STERIS currently has a consensus rating of "Moderate Buy" and an average target price of $275.20.

Insiders Place Their Bets

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the business's stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the transaction, the director owned 705 shares in the company, valued at $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.07% of the stock is owned by company insiders.

STERIS Price Performance

STERIS stock opened at $214.78 on Friday. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26. STERIS plc has a 52-week low of $209.98 and a 52-week high of $269.44. The company has a market cap of $21.06 billion, a price-to-earnings ratio of 29.96 and a beta of 0.95. The firm's fifty day moving average is $226.36 and its 200 day moving average is $244.69.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting analysts' consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same quarter in the previous year, the business earned $2.32 EPS. STERIS's revenue for the quarter was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Sell-side analysts forecast that STERIS plc will post 10.22 EPS for the current fiscal year.

STERIS Profile

STERIS Corporation NYSE: STE is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.